Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

32.29 +0.26 (+0.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 410,665
Open 31.52
Bid (Size) 31.52 (100)
Ask (Size) 34.25 (200)
Prev. Close 32.03
Today's Range 31.52 - 33.08
52wk Range 10.91 - 35.31
Shares Outstanding 101,192,921
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
From Spyre Therapeutics, Inc.
Via GlobeNewswire
Spyre Therapeutics' CEO Sells 15,000 Shares ↗
This biotech innovator in antibody therapies for inflammatory bowel disease reported a notable insider sale, according to a recent SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+5.6%
+5.6%
1 Month
-0.8%
-0.8%
3 Month
+31.4%
+31.4%
6 Month
+90.2%
+90.2%
1 Year
+55.1%
+55.1%

More News

Read More
News headline image
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga
News headline image
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
Via Benzinga
News headline image
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre (SYRE) Q2 R&D Up 23% Loss Narrows ↗
Via The Motley Fool
News headline image
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
Via Benzinga
News headline image
SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 ↗
Via InvestorPlace
News headline image
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 ↗
Via InvestorPlace
News headline image
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga
Topics Stocks

Frequently Asked Questions

Is Spyre Therapeutics, Inc. - Common Stock publicly traded?
Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?
Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?
The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market
What is the current price of Spyre Therapeutics, Inc. - Common Stock?
The current price of Spyre Therapeutics, Inc. - Common Stock is 32.29
When was Spyre Therapeutics, Inc. - Common Stock last traded?
The last trade of Spyre Therapeutics, Inc. - Common Stock was at 01/26/26 04:00 PM ET
What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?
The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 3.27B
How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?
Spyre Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.